Modality
Peptide
MOA
PLK4i
Target
BTK
Pathway
Angiogenesis
Endometrial CaHemophilia A
Development Pipeline
Preclinical
Nov 2019
→ Mar 2030
PreclinicalCurrent
NCT04071077
1,188 pts·Endometrial Ca
2019-11→2030-03·Completed
NCT03948626
285 pts·Endometrial Ca
2021-01→2025-11·Completed
1,473 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-164mo agoInterim· Endometrial Ca
2030-03-154.0y awayInterim· Endometrial Ca
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2025-11-16 · 4mo ago
Endometrial Ca
Interim
2030-03-15 · 4.0y away
Endometrial Ca
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04071077 | Preclinical | Endometrial Ca | Completed | 1188 | SRI-4 |
| NCT03948626 | Preclinical | Endometrial Ca | Completed | 285 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| Pemitinib | Xenon Pharma | Preclinical | BTK | |
| Terazumab | Rapport Ther | Phase 2 | BTK | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| RDY-3640 | Dr Reddy's | Preclinical | EZH2 |